Evaluation of Multisite Sampling to Detect C. Trachomatis or N. Gonorrheae

Status Recruiting

Clinical Trial Summary

Screening for STIs in MSM is based on multisite samples: urine, anal and oral for PCR targeting C. trachomatis, N. gonorrhoeae, M. genitalium and T. vaginalis, whereas only vaginal self-sampling is recommended in women. Recent publications and observations suggest that a substantial number of STIs are under diagnosed with the current recommendations. The main objective of the study is to assess the number and percentage of additional C. trachomatis and N. gonorrhoeae infections diagnosed by a multiple sampling strategy in women, particularly when the vaginal sampling is negative The secondary objective will assess the acceptability of anal and oropharyngeal self-sampling relative to vaginal self-sampling in women.

Clinical Trial Description

1500 women will be included in 5 different screening STIs centers in France based of the prevalence of STIs in this population (10% C. trachomatis) and the hypothesis that this new strategy allows to detect 20% more underdiagnosed STIs The sequential recruitment will concern women attending at one of the 5 STIs screening centers, whether they are symptomatic or not. If they agree to participate in the study, the patients will take the samples themselves from the 3 sites (vaginal, anal and oral self-sampling) using standard swabs (brand). The sample will immediately be placed in the transport medium in each of the 3 Sigma VCM tubes labeled by the patient, depending on the collection site. The study nurse will register the inclusion of patients, identify the tubes, collect information and send them to the local laboratory for the PCR to be performed. The study will be continued until the number of patients to be included for each of the centers is obtained. The anonymized data will be entered on an Excel database. The results of the PCRs will be collected a posteriori by the IDEs to populate the database. The PCR result will be given both qualitatively (positive/negative) and CT value for C. trachomatis and N. gonorrhoeae infections. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05872438
Study type	Interventional
Source	Centre Hospitalier Régional d'Orléans
Contact	Thierry PRAZUCK, Dr
Phone	02 38 22 95 93
Email	thierry.prazuck@chr-orleans.fr
Status	Recruiting
Phase	N/A
Start date	April 14, 2023
Completion date	April 2024

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03098394` - Use of a Rapid Test for Gonorrhea & Chlamydia for Women Presenting With Possible Sexually Transmitted Infections	N/A
Completed	`NCT03186183` - GPS: Adaptation Trial of an HIV Prevention Counselling Program for HIV-positive and HIV-negative Gay and Bisexual Men	N/A
Completed	`NCT05504954` - A Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women: IMARA SA	N/A
Completed	`NCT01387646` - Behavioral Intervention for Minority Adolescent Women	Phase 2
Terminated	`NCT00170534` - Intervention for Male STDs in India	N/A
Recruiting	`NCT04585165` - User-friendly HIV Testing and Counseling Services
Completed	`NCT04021953` - The People Like Us Evaluation Study	N/A
Completed	`NCT02993185` - Making Healthy Decisions: A Trial Evaluating the "Your Move" Teen Pregnancy-prevention Intervention	N/A
Active, not recruiting	`NCT01088542` - The Community Youth Development Study: A Test of Communities That Care	N/A
Completed	`NCT01379599` - Brief Intervention to Reduce STDs in ER Drug Users	Phase 3
Recruiting	`NCT05244967` - Epidemiology of Sexually Transmitted Infections and Its iMpAcT on fEmale Infertility
Recruiting	`NCT05766904` - Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections	Phase 3
Completed	`NCT00170430` - Reducing Vaginal Infections in Women	Phase 3
Completed	`NCT03431168` - A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV	Phase 2
Recruiting	`NCT04446611` - Clinical Study of STI Screening to Prevent Adverse Birth and New-born Outcomes	N/A
Completed	`NCT02868346` - Improving the Diagnosis of Sexually Transmitted Infections in Emergency Rooms	N/A
Completed	`NCT02740998` - Long-Acting Progestin Contraception and the Vaginal Microbiome
Completed	`NCT04207151` - Expanding PrEP By Embedding Unannounced SNAPS Navigators in High STI Testing Clinical Sites	N/A
Completed	`NCT02498067` - rPlan Multimedia Dual Protection Intervention to Reduce Health Disparities	N/A
Active, not recruiting	`NCT05541081` - Investigating Point-of-care Diagnostics for Sexually Transmitted Infections and Antimicrobial Resistance in Primary Care in Zimbabwe	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of Multisite Sampling to Detect C. Trachomatis or N. Gonorrheae Compared With Vaginal Sampling in Women at Risk for Sexually Transmitted Infections — SIST'RS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms